Spine Tumor Surgery in India and UAE | Complete Patient Guide

• ELIGIBLE CANDIDATES:

• Patients with radiographically confirmed spinal tumor causing progressive neurological deficits (myelopathy, radiculopathy, or cauda equina syndrome) regardless of tumor etiology

• Patients with spinal instability confirmed by a SINS score of 7 or above, with or without neurological compromise

• Primary spinal tumor patients (chordoma, giant cell tumor, osteosarcoma, Ewing's sarcoma, hemangioblastoma) where wide or marginal surgical margins are achievable based on WBB staging

• Patients with solitary or oligometastatic spinal disease and controlled systemic disease, suitable for separation surgery followed by stereotactic body radiotherapy (SBRT/SRS)

• Patients with intradural-extramedullary tumors (meningiomas, schwannomas, neurofibromas) where gross total resection carries acceptable neurological risk as assessed by intraoperative neurophysiological monitoring (IONM) feasibility

• Patients with intramedullary tumors (ependymoma — WHO Grade II; hemangioblastoma) where a tumor-cord interface is identifiable on gadolinium-enhanced MRI, permitting safe gross total resection

• Patients with acute or subacute neurological deterioration requiring emergency decompression (Frankel/ASIA Grade A–D) within a surgical window ideally under 24–48 hours of symptom onset

• Patients deemed medically fit for general anesthesia with acceptable cardiopulmonary reserve (ASA Class I–III)

• REQUIRED DIAGNOSTIC WORKUP:

• Gadolinium-enhanced MRI of entire spine (whole-spine survey to exclude synchronous disease) with dedicated thin-slice sequences at the index level

• CT scan (bone windows) of involved vertebral segment for surgical planning: assess cortical integrity, pedicle morphology, and fusion level selection

• PET-CT (FDG) or bone scintigraphy for systemic staging and identification of additional metastatic sites (mandatory for metastatic and primary malignant tumors)

• CT-guided needle biopsy of the spinal lesion if histological diagnosis is not established from a prior systemic tumor (avoid biopsy tracts that contaminate surgical field in en bloc resection candidates)

• Digital subtraction angiography (DSA) ± preoperative tumor embolization for hypervascular tumors (renal cell carcinoma metastases, paragangliomas, hemangiomas) 24–48 hours pre-surgery

• Neurophysiological baseline assessment (EMG, NCS) if preoperative radiculopathy or myelopathy is present

• Echocardiography (ECHO) and pulmonary function tests (PFTs/spirometry) for patients with known cardiopulmonary disease or planned thoracotomy approach

• Serum tumor markers as clinically indicated (PSA, CA-125, AFP, LDH, serum protein electrophoresis for myeloma)

• Bone mineral density (DEXA scan) if osteoporosis is suspected — impacts pedicle screw pullout strength and instrumentation planning

• Multidisciplinary tumor board review of all imaging and pathology prior to surgical planning

• RELATIVE CONTRAINDICATIONS:

• Medically unresectable systemic disease with life expectancy under 3 months (palliative radiation ± minimal stabilization preferred)

• ASA Class IV–V with prohibitive perioperative cardiac or respiratory risk

• Coagulopathy unresponsive to correction (INR > 1.5 uncorrected; platelet count < 50,000/µL)

• Prior high-dose radiation to the operative field without adequate recovery interval (increases wound dehiscence and CSF leak risk significantly)

• ASIA Grade A (complete motor and sensory loss) for more than 24–48 hours with no neurophysiological evidence of residual cord function (surgical decompression unlikely to restore function; risk-benefit reassessment required)

• Widespread bony destruction at multiple contiguous levels making stable reconstruction biomechanically unfeasible

SURGICAL APPROACHES — STANDARD TO ADVANCED:

1. POSTERIOR DECOMPRESSION WITH PEDICLE SCREW INSTRUMENTATION AND FUSION (Standard Open)

The most widely performed operation for metastatic thoracic and lumbar cord compression. A midline posterior incision exposes the laminae and pedicles; laminectomy decompresses the dural sac; bilateral pedicle screws spanning 2–3 levels above and below the tumor provide rigid three-column stabilization using titanium rod-and-screw constructs. Posterolateral fusion with autograft or allograft bone graft is performed. Increasingly supplemented with vertebroplasty or kyphoplasty cement augmentation of tumor-involved bodies for anterior column support. Typical operative time: 3–5 hours.

2. SEPARATION SURGERY + STEREOTACTIC BODY RADIOTHERAPY (SBRT) — Advanced Standard of Care

Developed at Memorial Sloan Kettering, this paradigm-shifting approach involves a posterior circumferential decompression creating a 2–3 mm circumferential 'separation' between residual tumor and the dural sac, followed by pedicle screw stabilization. It deliberately avoids aggressive en bloc resection in metastatic patients, instead relying on high-dose SBRT (24 Gy in 1–2 fractions or 27–30 Gy in 3 fractions) delivered post-operatively to ablate the residual epidural tumor with millimetric precision. Local control rates exceed 80–90% at 1 year. This strategy is the current international standard for most radiosensitive and radio-resistant metastatic tumors (including renal cell carcinoma and melanoma).

3. EN BLOC VERTEBRECTOMY (Tomita Procedure / WBB-Guided Resection)

Reserved for primary malignant spinal tumors (chordoma, osteosarcoma, Ewing's sarcoma) and select solitary metastases. The entire vertebral body, posterior elements, and surrounding soft tissue are resected as a single intact specimen, achieving wide or marginal oncological margins. A combined anterior-posterior or posterior-only approach (depending on spinal level and WBB zone) is used. The defect is reconstructed with an expandable titanium cage (e.g., Synex, Pyramesh) or carbon fiber cage packed with bone graft, secured with long-segment posterior instrumentation. For cervical spine tumors, anterior cervical corpectomy with cage and plate reconstruction is standard. This is technically the most demanding spinal oncology operation, requiring surgeons experienced in both spine surgery and surgical oncology principles.

4. MINIMALLY INVASIVE SPINE (MIS) APPROACHES

• Percutaneous pedicle screw fixation: Fluoroscopy- or navigation-guided cannulated screws placed through stab incisions, dramatically reducing blood loss (estimated blood loss 200–400 mL vs. 800–1,500 mL open) and wound complications in immunocompromised or frail oncology patients. Particularly valuable in patients with poor wound healing potential (prior radiation, steroid use, malnutrition).

• MIS lateral transpsoal approach (XLIF/DLIF): Allows anterior column reconstruction through a retroperitoneal flank incision without thoracotomy, reducing pulmonary morbidity in thoracolumbar junction tumors.

• Endoscopic-assisted tumor resection: Thoracoscopic or posterior endoscopic approaches for anterior column tumors with reduced chest wall morbidity.

• Kyphoplasty/Vertebroplasty: Fluoroscopy-guided percutaneous cement injection for painful vertebral hemangiomas or impending pathological fractures from lytic metastases when surgery is not indicated; provides immediate pain relief in 70–85% of patients.

5. INTRAMEDULLARY TUMOR RESECTION (Ependymoma, Hemangioblastoma, Astrocytoma)

Requires posterior midline myelotomy — a precision incision through the dorsal midline of the spinal cord — under continuous intraoperative neurophysiological monitoring (IONM) with motor evoked potentials (MEPs), somatosensory evoked potentials (SSEPs), and D-wave monitoring. Ultrasonic surgical aspirator (CUSA — Cavitron Ultrasonic Surgical Aspirator) and laser (CO₂ or KTP) facilitate safe dissection within cord tissue. Gross total resection is achievable in 90–95% of ependymomas given their well-demarcated pseudocapsule, but only 30–50% of astrocytomas (which are infiltrative and lack a clear plane). Intraoperative MRI (iMRI) is increasingly used in leading centers to confirm resection adequacy without repositioning the patient.

6. ROBOTICS-ASSISTED SPINE SURGERY (Mazor X Stealth, ROSA Spine, ExcelsiusGPS)

Robotic platforms integrated with real-time 3D navigation provide sub-millimeter accuracy for pedicle screw trajectory planning and placement, reducing neurological injury from malpositioned screws by up to 5-fold compared to freehand techniques. Particularly critical in tumor cases where altered anatomy from vertebral destruction, prior surgery, or radiation makes landmark-based screw placement hazardous. Multiple centers in India (Fortis, Apollo, Medanta) and the UAE (Cleveland Clinic Abu Dhabi, Burjeel Medical City) have active robotic spine surgery programs.

7. INTRAOPERATIVE NEUROPHYSIOLOGICAL MONITORING (IONM)

Mandatory for all intradural procedures and recommended for all extradural procedures involving cord-level decompression. Continuous MEP, SSEP, and EMG monitoring provides real-time feedback on cord and nerve root function, allowing the surgeon to modify the operative strategy before permanent neurological injury occurs. A ≥50% reduction in MEP amplitude or ≥10% increase in SSEP latency triggers an immediate surgical pause and corrective action protocol.

8. ADJUVANT ONCOLOGICAL THERAPIES (Integral to Surgical Planning)

• SBRT/SRS: CyberKnife or Varian TrueBeam STx linear accelerators used post-separation surgery

• Targeted therapy: VEGFR inhibitors (sunitinib, pazopanib) for renal cell carcinoma metastases; BRAF inhibitors (vemurafenib) for melanoma metastases — coordinated with surgical timing to minimize wound healing impairment

• Immunotherapy: Checkpoint inhibitors (pembrolizumab, nivolumab) — typically held 4–6 weeks perioperatively

• Bisphosphonates/Denosumab: Osteoclast inhibition for skeletal metastases and giant cell tumor of bone

• Hormonal therapy: For breast and prostate cancer spinal metastases

PRE-OPERATIVE PHASE (Weeks 1–3 Before Surgery):

Step 1 — Remote Consultation and Case Review (Days 1–7):

The patient submits MRI, CT, PET-CT, biopsy reports, and systemic oncology records to GAF Healthcare's spine oncology panel. A board-certified spine oncology surgeon and a multidisciplinary team conduct a virtual tumor board review. The surgical plan — approach, extent of resection, instrumentation strategy, and adjuvant treatment sequencing — is communicated to the patient with a written opinion within 48–72 hours. If tissue diagnosis is not established, CT-guided biopsy is scheduled as the first procedure upon arrival.

Step 2 — Pre-Surgical Medical Clearance (Days 7–14):

On arrival, the patient undergoes in-country workup: repeat MRI with surgical planning sequences, CT angiography if vessel involvement is suspected, ECHO and PFTs for patients undergoing anterior approaches, hematological optimization (correction of anemia with preoperative EPO or iron infusion if Hb < 10 g/dL, transfusion if < 8 g/dL), and nutritional assessment. Steroids (dexamethasone 8–16 mg/day in divided doses) are initiated for patients with cord edema and significant neurological compromise. Preoperative embolization of hypervascular tumors is performed 24–48 hours before surgery by interventional neuroradiology.

Step 3 — Surgical Team Briefing and IONM Setup (Day of Surgery – 2 hours pre-op):

Anesthesia and neurophysiological monitoring teams establish baseline MEP, SSEP, and EMG waveforms under total intravenous anesthesia (TIVA with propofol and remifentanil — mandatory for accurate IONM). Blood products (packed red cells, FFP, platelets, cryoprecipitate) are cross-matched and available. Cell-saver autotransfusion is prepared for anticipated blood loss > 500 mL.

PROCEDURE (Day 0 — Operative Day):

Step 4 — Surgery (Duration 3–10 hours depending on procedure):

• Patient is positioned prone (posterior approach) or lateral decubitus (anterior/lateral approach) with meticulous pressure point padding and eye protection.

• Intraoperative 3D navigation or robotic registration is performed after patient positioning using reference arrays or intraoperative CT (O-arm or Brainlab).

• Posterior exposure, laminectomy/hemilaminectomy or transpedicular corpectomy as planned; intradural tumor: microsurgical myelotomy and tumor dissection under 4–40× magnification with CUSA.

• Instrumentation: pedicle screws placed under navigation/robotic guidance; cage reconstruction of anterior column if corpectomy performed; rod-and-screw assembly torqued to specification.

• Wound closure in anatomical layers with subfascial drain placed; vancomycin powder may be applied to reduce surgical site infection risk.

• Intraoperative MRI performed if available for resection adequacy confirmation before wound closure.

POST-OPERATIVE RECOVERY PHASE:

Step 5 — Intensive Care / High-Dependency Unit (Days 1–3 post-op):

Patient is monitored in ICU or HDU for neurological status (hourly motor assessments), hemodynamic stability, drain output, pain control (multimodal: IV paracetamol, dexamethasone taper, opioids via PCA pump, gabapentin for neuropathic pain), and thromboembolic prophylaxis (LMWH initiated 24–48 hours post-op; sequential compression devices intraoperatively and immediately post-op). Drain is removed when output < 30 mL/8 hours.

Step 6 — Ward and Early Mobilization (Days 3–7):

Spine-trained physiotherapist initiates bed mobility exercises on Day 1 post-op; supervised sitting on Day 2; standing and transfer training on Day 3 if neurologically stable. Thoracolumbosacral orthosis (TLSO brace) is fitted for lumbothoracic procedures involving corpectomy. Occupational therapist assesses activities of daily living (ADL) capacity. Wound inspection daily; sutures/staples removed at 12–14 days.

Step 7 — Hospital Discharge Planning and Oncology Coordination (Days 7–14):

Discharge occurs when the patient ambulates independently (with or without assistive device), pain is controlled on oral analgesics, wound is clean and healing, and SBRT/SRS planning (if separation surgery performed) has been initiated. Radiation oncology simulation CT is typically performed before discharge so SBRT can begin 2–4 weeks post-operatively (allowing wound healing without delaying radiation to residual tumor).

Step 8 — Post-Discharge In-Country Rehabilitation (Weeks 2–6):

Patient stays in a GAF Healthcare partner recovery apartment or rehabilitation facility near the treating hospital. Outpatient physiotherapy 5 days/week: progressive gait training, core stabilization exercises, neurological recovery exercises tailored to deficit pattern. Follow-up MRI/CT spine at 4–6 weeks to assess hardware position and early tumor response. Wound review at 2 weeks; suture removal if absorbable sutures were not used.

Step 9 — Fit-to-Fly Assessment and Repatriation (Weeks 4–8):

The treating surgeon conducts a formal fit-to-fly assessment. Prerequisites: wound fully healed, no active CSF leak, VTE prophylaxis established (oral anticoagulant or LMWH for flight > 4 hours), neurological status stable or improving, brace compliance confirmed, and repatriation medical summary with imaging prepared. Long-haul economy class flight is contraindicated for patients with significant residual weakness or venous thromboembolism risk — business/premium economy recommended. Medical escort arranged through GAF Healthcare if the patient's condition requires clinical supervision during repatriation.